Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Director | September 08, 2026 | September 08, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director · President, Interim CFO | May 31, 2024 | May 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date September 08, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,800,111 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 784,314 · Balance 2,800,111 F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2030-03-25 | Direct | 0 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 784,314 · Balance 0 F3: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. |
| Common StockSEC Table I · non-derivative | IndirectBy Garret Gallagher - Custodian UTMA/UGMA | 83,000 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 83,000 F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein. F2: These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein.
F2: These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.
Zentalis Pharmaceuticals, Inc.
Report date May 31, 2024 · Filed May 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 633,680 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Sale · Disposed 9,597 · Balance 633,680 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 24, 2020 Filed Feb 3, 2021 22:54 UTC Amendment | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,103 | $54.77 | $169,935.80 |
DisclosureSEC source: 0001725160-21-000019 · wf-form4a_161239283938848.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As custodian for son Disclosed balance after: 15,370 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. F2 · price: Due to a clerical error, the Reporting Person's original Form 4 filed on December 28, 2020 omitted the weighted average sale price. This Form 4/A is being filed to add the weighted average sale price to column 4. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.15 to $55.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,118 | $57.93 | $64,771.22 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 11 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,192 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F12 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $57.85 to $57.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 13,044 | $57.54 | $750,615.68 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 10 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,310 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F11 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $56.85 to $57.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,226 | $56.08 | $124,836.31 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 9 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,354 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F10 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $55.81 to $56.52. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,800 | $55.37 | $265,781.28 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 8 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,580 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.80 to $55.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,385 | $54.19 | $75,051.77 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 7 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,380 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.70 to $54.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 405 | $54.39 | $22,026.45 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 6 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,765 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.15 to $54.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,158 | $53.71 | $277,041.85 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 5 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,170 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $54.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,006 | $52.53 | $52,844.48 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,328 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.15 to $53.13. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 123 | $50.84 | $6,253.20 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,334 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.53 to $51.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,014 | $51.17 | $205,407.62 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,457 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.02 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 9, 2020 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,460 | $50.76 | $175,638.94 |
DisclosureSEC source: 0001725160-20-000060 · wf-form4_160747789649528.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,471 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.02 to $51.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,300 | $52.71 | $121,223.34 |
DisclosureSEC source: 0001725160-20-000050 · wf-form4_160703619626484.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,931 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.39 to $53.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,203 | $51.65 | $165,448.40 |
DisclosureSEC source: 0001725160-20-000050 · wf-form4_160703619626484.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 619,231 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.38 to $52.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,468 | $50.86 | $176,397.74 |
DisclosureSEC source: 0001725160-20-000050 · wf-form4_160703619626484.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,434 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.35 to $51.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,029 | $49.82 | $51,264.68 |
DisclosureSEC source: 0001725160-20-000050 · wf-form4_160703619626484.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,902 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.29 to $50.27. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:33 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,165 | $47.30 | $55,107.53 |
DisclosureSEC source: 0001725160-20-000039 · wf-form4_160635438045598.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,931 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.03 to $47.695. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:33 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,835 | $46.44 | $410,273.55 |
DisclosureSEC source: 0001725160-20-000039 · wf-form4_160635438045598.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,096 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.00 to $46.985. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 147,788 shares of common stock received on October 28, 2020 in a pro-rata distribution in-kind that was exempt from reporting under Rule 16a-9. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 01:11 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries B Warrant (right to buy) · Derivative | 1,574 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001140361-20-026656 · form4.xml · derivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,574 Underlying: Common Stock · 1,574 shares Expires 2022-01-28 F2 · shares: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $50,000. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 01:11 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries A Warrant (right to buy) · Derivative | 13,394 | Not disclosed Strike: $4.48 | Not disclosed |
DisclosureSEC source: 0001140361-20-026656 · form4.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,394 Underlying: Common Stock · 13,394 shares Expires 2025-11-19 F2 · derivative.exercise_price: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $50,000. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 01:11 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 8,865 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-026656 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,354 F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $50,000. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:03 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001140361-20-025529 · form4.xml · derivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-11-11 F1 · derivative.exercise_date: Vesting in 12 equal monthly increments beginning on November 30, 2020, except for October 31, 2021 when the balance vests. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 23:22 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 52,825 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001596771-20-000112 · primary_doc.xml · derivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,825 Underlying: Common Stock · 52,825 shares Expires 2029-12-27 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire, pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F3 · derivative.exercise_date: 1,479 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2022, subject to continued service. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 23:22 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 35,663 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001596771-20-000112 · primary_doc.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,663 Underlying: Common Stock · 35,663 shares Expires 2028-12-20 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire, pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 23:22 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 14,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-20-000112 · primary_doc.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,489 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire, pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:30 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 73,478 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010604 · doc4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,143 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest over a fifteen month period following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.